Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kyowa Hakko’s Cancer Pain Drug Enters Phase III Trial

This article was originally published in PharmAsia News

Executive Summary

Kyowa Hakko announced that sublingual cancer pain reliever KW-2246 entered Phase III trials in Japan. The main ingredient for KW-2246 is fentanyl. Kyowa obtained the exclusive rights to develop and market in Japan from a 2003 license agreement with Swedish company Orexo. Since this March, Kyowa has stopped marketing a cancer pain patch due to a contractual problem. (Click here for more - Japanese language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts